| __timestamp | Amicus Therapeutics, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 9335772 |
| Thursday, January 1, 2015 | 47269000 | 12390000 |
| Friday, January 1, 2016 | 71151000 | 25602000 |
| Sunday, January 1, 2017 | 88671000 | 21262000 |
| Monday, January 1, 2018 | 127200000 | 28430000 |
| Tuesday, January 1, 2019 | 169861000 | 40849000 |
| Wednesday, January 1, 2020 | 156407000 | 60210000 |
| Friday, January 1, 2021 | 192710000 | 83664000 |
| Saturday, January 1, 2022 | 213041000 | 104097000 |
| Sunday, January 1, 2023 | 275270000 | 106916000 |
Unlocking the unknown
In the competitive world of biotechnology, managing operational costs is crucial. Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Amicus saw a staggering increase of over 1,200% in SG&A expenses, peaking at approximately $275 million in 2023. In contrast, Iovance's expenses grew by about 1,050%, reaching around $107 million in the same year. This divergence highlights Amicus's aggressive expansion strategy compared to Iovance's more conservative approach. Understanding these trends provides valuable insights into each company's operational focus and strategic priorities. As the biotech industry continues to evolve, monitoring such financial metrics will be key to predicting future market leaders.
Explore how two biotech giants manage their operational costs over time.
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: AstraZeneca PLC vs Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.
Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?